This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.
Despite a reduction in pertussis among younger children and infants, rates of pertussis-related sickness and death remain high compared with rates for other vaccine-preventable diseases in England and Wales.
Universal screening of pregnant women is feasible and has led to immunisation in nearly all identified cases in Denmark. As a consequence of the study the National Board of Health has made universal HBsAg screening of pregnant women permanent in the country.
Starting 15 September 2011, ECDC will be coordinating the former EUVAC.NET network. It is a surveillance network covering measles, mumps, rubella, congenital rubella, pertussis and varicella EU Member States and three countries of the European Economic Area. Data will be hosted by the European Surveillance System (TESSy) at ECDC.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.